(Date:12/15/2009)... -- Repligen Corporation (Nasdaq: RGEN ) today ... research funding to support the ongoing development of ... Dystrophy Association (MDA). This grant will support ... GMP manufacture of a drug candidate for human ... only provides important funding for Repligen,s research but ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, The Future of Orphan ... Pipeline Analysis and Reimbursement ,, ... Summary ,, The author has ... Orphan Diseases Therapeutics - Market Forecasts to ...
(Date:12/15/2009)... 15 AstraZeneca (NYSE: ... (UVa) in Charlottesville, today announced that they ... to enhance development of new treatments primarily ... secondary focus on peripheral vascular disease (PAD). ... The collaborative preclinical research projects will focus ...
(Date:12/15/2009)... (NYSE: MOS ) plans to issue its ... tables on Tuesday, January 5, 2010, after the close ... Results will be available on Mosaic,s website at mosaicco.com/investors. ... call with presentation slides on Wednesday, January 6, 2010, ... at 11:00 a.m. Eastern Standard Time (10:00 a.m. Central ...
Breaking Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2... Thermo Fisher,Scientific Inc. (NYSE: TMO ), the world ... a record $2.55 billion in the first quarter,of 2008, ... revenues by 4%, and acquisitions, net of divestitures, increased,revenues ... $.53 in 2008,versus $.31 in the year-ago period. GAAP ...
... Transformation to Commercial Operating ... ... CTIC ; MTAX) today announced that Craig W. Philips, most ... President of CTI with direct responsibilities for all Development and,Commercial Operations, ...
... RICHMOND, Calif., April 23 Sangamo,BioSciences, Inc. (Nasdaq: ... first quarter 2008 financial results on Wednesday, April 30,2008, ... followed by a,conference call at 2:00 p.m. PT, which ... During the conference call, the company will review,the financial ...
Other Biology Technology:Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 2Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 3Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 5Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 6Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 7Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 8Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 9Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 10Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 11Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 12Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 13Veteran Drug Industry Executive to Become President of CTI 2Veteran Drug Industry Executive to Become President of CTI 3Veteran Drug Industry Executive to Become President of CTI 4Sangamo BioSciences Announces First Quarter Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter Conference Call and Webcast 3RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
GOAT ANTI FRK...
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
MOUSE ANTI DUCK IgY LIGHT CHAIN...
Biology Products:Biology NavigationMedical Navigation